Free Trial

Bon Natural Life (BON) Competitors

$1.68 -0.09 (-5.08%)
As of 05/28/2025 04:00 PM Eastern

BON vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUW

Should you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry.

Bon Natural Life vs.

180 Life Sciences (NASDAQ:ATNFW) and Bon Natural Life (NASDAQ:BON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.

180 Life Sciences and Bon Natural Life both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
180 Life SciencesN/AN/A
Bon Natural LifeOutperform Votes
No Votes
Underperform Votes
1
100.00%

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Bon Natural Life N/A N/A N/A

In the previous week, Bon Natural Life had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Bon Natural Life and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat Bon Natural Life's score of 0.80 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
180 Life Sciences Very Positive
Bon Natural Life Positive

0.6% of Bon Natural Life shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Bon Natural Life$23.84M0.01N/AN/AN/A

Summary

Bon Natural Life beats 180 Life Sciences on 4 of the 5 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BON vs. The Competition

MetricBon Natural LifeMedicinal Chemicals IndustryManufacturing SectorNASDAQ Exchange
Market Cap$281,000.00$432.59M$2.02B$8.46B
Dividend YieldN/AN/A2.64%4.18%
P/E RatioN/A21.5322.6719.78
Price / Sales0.014.0158.59138.40
Price / CashN/AN/A51.7234.64
Price / BookN/AN/A2.064.54
Net IncomeN/AN/A-$292.00M$247.85M
7 Day PerformanceN/A8.39%0.46%1.68%
1 Month PerformanceN/A44.09%6.81%8.76%
1 Year PerformanceN/AN/A14.69%9.69%

Bon Natural Life Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BON
Bon Natural Life
N/A$1.68
-5.1%
N/AN/A$281,000.00$23.84M0.00100News Coverage
Short Interest ↓
Gap Down
ATNFW
180 Life Sciences
N/A$0.01
+1.4%
N/A-13.8%$0.00N/A0.007Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522,000.000.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
+5.3%
N/A-83.5%$0.00N/A0.002Gap Up
AIMDW
Ainos
N/A$0.21
+48.9%
N/AN/A$0.00$106,207.000.0040Gap Down
ALVOW
Alvotech
N/A$1.80
flat
N/A-29.3%$0.00$585.60M0.004Gap Down
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.02
+25.0%
N/A-82.7%$0.00N/A0.0015High Trading Volume
BFRIW
Biofrontera
N/A$0.09
-18.1%
N/A+100.7%$0.00$38.00M0.0070Gap Down
BTMDW
biote
N/A$0.02
flat
N/A-94.9%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.10
-4.6%
N/A-81.3%$0.00N/A0.008Short Interest ↓
CELUW
Celularity
N/A$0.04
-33.3%
N/A+157.1%$0.00$54.22M0.00220

Related Companies and Tools


This page (NASDAQ:BON) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners